格隆汇11月27日丨金石亚药(300434.SZ)在投资者互动平台表示，公司是国内感冒药一线产品"快 克"和"小快克"的品牌缔造者和拥有者。经过二十多年的品牌积累，已经成功搭建围绕成人及儿童感咳 领域的产品集群。其中，重点产品有"快克"复方氨酚烷胺胶囊适用于缓解普通感冒及流行性感冒的各种 症状，也可用于流行性感冒的预防和治疗；"小快克"小儿氨酚黄那敏颗粒适用于缓解儿童普通感冒及流 行性感冒引起的各种症状；"快克清"磷酸奥司他韦胶囊适用于成人和1岁及1岁以上儿童的甲型和乙型流 感治疗以及成人和13岁及13岁以上青少年的甲型和乙型流感的预防。此外，还有愈美甲麻敏糖浆、蒲地 蓝消炎片、抗病毒口服液、复方金银花颗粒、感冒清热颗粒、布洛伪麻片、枇杷止咳颗粒、布洛芬颗 粒、小儿咳喘灵颗粒、板蓝根颗粒等多个产品，满足消费者预防、缓解、治疗感冒的多方面需求。 ...

格隆汇11月27日丨金石亚药(300434.SZ)在投资者互动平台表示，公司是国内感冒药一线产品"快 克"和"小快克"的品牌缔造者和拥有者。经过二十多年的品牌积累，已经成功搭建围绕成人及儿童感咳 领域的产品集群。其中，重点产品有"快克"复方氨酚烷胺胶囊适用于缓解普通感冒及流行性感冒的各种 症状，也可用于流行性感冒的预防和治疗；"小快克"小儿氨酚黄那敏颗粒适用于缓解儿童普通感冒及流 行性感冒引起的各种症状；"快克清"磷酸奥司他韦胶囊适用于成人和1岁及1岁以上儿童的甲型和乙型流 感治疗以及成人和13岁及13岁以上青少年的甲型和乙型流感的预防。此外，还有愈美甲麻敏糖浆、蒲地 蓝消炎片、抗病毒口服液、复方金银花颗粒、感冒清热颗粒、布洛伪麻片、枇杷止咳颗粒、布洛芬颗 粒、小儿咳喘灵颗粒、板蓝根颗粒等多个产品，满足消费者预防、缓解、治疗感冒的多方面需求。 ...

Core Insights - Sichuan Jinshi Yao Pharmaceutical Co., Ltd. has made significant progress in its strategic layout in the dermatological drug sector by launching the first commercialized dexamethasone ointment in China under its children's drug brand "Xiaokuai Ke" in collaboration with the innovative dermatological drug brand "Shushining" [1] - The dexamethasone ointment adheres to the principle of "simplicity equals safety," containing only the active ingredient dexamethasone and the base white vaseline, eliminating potential allergens such as preservatives, emulsifiers, and fragrances, addressing the core pain points of pediatric medication safety [1] Market Opportunity - At present, atopic dermatitis (AD) has become a core challenge in health management for Chinese families, with a patient base of 70.7 million in 2022, nearly half of whom are children and adolescents [2] - The market for AD is projected to grow at a compound annual growth rate (CAGR) of 18.6%, expected to exceed 30.5 billion yuan by 2030, with the children's segment anticipated to surpass 4.5 billion yuan [3] Product Innovation - The dexamethasone ointment is the only approved formulation of its kind in China, featuring an oil-based matrix that enhances penetration and reduces stickiness compared to traditional creams and ointments, significantly improving barrier repair efficiency [5] - The product's formulation, which includes only dexamethasone and white vaseline, minimizes skin irritation and damage, aligning with the WHO's recommendations for pediatric use of topical corticosteroids [4][5] Strategic Positioning - The launch of the dexamethasone ointment represents a strategic move for Jinshi Yao, enhancing its product matrix in the children's dermatological drug market and solidifying its brand position in the pediatric pharmaceutical sector [6][8] - The company has established six core health product lines, with the dexamethasone ointment serving as the first specialized pediatric dermatological drug, contributing to a comprehensive health ecosystem that addresses various life stages and health management needs [7][8] Long-term Vision - Jinshi Yao aims to build a sustainable health ecosystem, with the launch of the dexamethasone ointment being a critical piece of its dermatological strategy, reflecting a commitment to long-term growth and investment value [6][9] - The company's mission to "provide good medicine and serve society" aligns with national health strategies, particularly in safeguarding children's health, thereby enhancing its social responsibility and market position [10][11]

Group 1: Company Strategy and Development - The company adheres to a dual strategy of independent and collaborative research and development, enhancing its long-term development through strategic investments and internal resource integration [1] - The company aims to become a trusted and preferred provider of professional healthcare products, focusing on a unified operational system across R&D, marketing, and production [2] - The company plans to implement a four-pronged growth model encompassing OTC, prescription drugs, traditional Chinese medicine, and health products to support high-quality development [2] Group 2: Marketing and Sales Achievements - The company has established a comprehensive marketing system, covering over 3,000 chain pharmacies and approximately 240,000 cooperative chain stores, reaching over 90% of cities and 70% of districts nationwide [2] - The company’s online channel strategy includes partnerships with e-commerce platforms to enhance product accessibility and consumer engagement [2] Group 3: Financial Performance - In 2024, the pharmaceutical segment generated revenue of 915 million yuan, accounting for 82.96% of total revenue, with the "Kuaike" series contributing 612 million yuan, representing 55.49% of total revenue [3] - The company’s cold and flu medications account for approximately 56% of total revenue [4] Group 4: Product Development and Market Position - The "Kuaike" cold medicine has ranked first in the annual comprehensive statistics of non-prescription drugs in China for three consecutive years from 2021 to 2023 [3] - The company has successfully launched the "Kuaike Qing" oseltamivir capsules and has received re-listing permits for other products [1] Group 5: Future Plans and Challenges - The company is actively preparing for the flu season by optimizing production capacity and ensuring smooth supply channels [5] - The company is exploring opportunities in traditional Chinese medicine, developing high-quality products to enhance market share in this sector [5]